TANVEX BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.2 TWD | -3.10% |
|
-5.59% | -35.18% |
| 03-14 | Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-06 | Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer | CI |
Chart calendar Tanvex BioPharma, Inc.
31f3443bf34.Kh45-vS-JFo4dvL1_pmQR8X0JAQthfASGQuxlvyrZ2g.XFt4yJz7CQlfRrbFlNPzFomzZjRF57Z7cWb296XnFxxSS26Dou9SN3EQow~937ff0bc1554bf284918a653a3ca95ac
Upcoming events on Tanvex BioPharma, Inc.
Past events on Tanvex BioPharma, Inc.
| 09/05/2024 | Q1 2024 Earnings Release (Projected) |
| 08/04/2024 | March 2024 Sales and Revenue Release |
| 01/04/2024 07:30 | MasterLink Securities Investor Conference |
| 14/03/2024 07:29 | Q4 2023 Earnings Release |
| 06/03/2024 07:53 | February 2024 Sales and Revenue Release |
| 07/02/2024 06:46 | January 2024 Sales and Revenue Release |
| 10/01/2024 06:06 | December 2023 Sales and Revenue Release |
| 08/12/2023 06:25 | November 2023 Sales and Revenue Release |
| 13/11/2023 08:54 | Q3 2023 Earnings Release |
| 08/11/2023 08:43 | October 2023 Sales and Revenue Release |
| 05/10/2023 06:42 | September 2023 Sales and Revenue Release |
| 12/05/2023 08:00 | Masterlink Securities's Investor Conference |
| 10/04/2023 09:39 | March 2023 Sales and Revenue Release |
| 09/03/2023 09:34 | February 2023 Sales and Revenue Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 |
|---|---|---|---|---|
|
Net sales Million TWD | Released Forecast Spread | 0,00 0,00 - | 0,30 0,00 - | 5,41 0,00 - |
|
EBITDA Million TWD | Released Forecast Spread | -2 112 -2 193 3.68% | -1 879 -1 991 5.62% | -1 356 -1 713 20.86% |
|
EBIT Million TWD | Released Forecast Spread | -2 328 -2 345 0.72% | -2 100 -2 198 4.48% | -1 599 -1 941 17.61% |
|
Earnings before Tax (EBT) Million TWD | Released Forecast Spread | -2 274 -2 281 0.3% | -2 104 -2 177 3.34% | -1 543 -1 885 18.13% |
|
Net income Million TWD | Released Forecast Spread | -2 274 -2 281 0.3% | -2 104 -2 177 3.34% | -1 543 -1 885 18.13% |
|
EPS TWD | Released Forecast Spread | -27,8 -27,2 -2.21% | -23,5 -24,7 4.85% | -14,2 -18,1 21.65% |
| Announcement Date | 26/03/20 | 29/03/21 | 28/03/22 |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|
|
Net sales Million TWD | Released Forecast Spread | 4,84 0,00 - | 3,04 3,00 1.47% | 8,33 3,00 177.67% | |
|
EBITDA Million TWD | Released Forecast Spread | -271 -455 40.36% | |||
|
EBIT Million TWD | Released Forecast Spread | -337 -508 33.62% | -418 -329 -26.97% | -392 -338 -15.85% | |
|
Earnings before Tax (EBT) Million TWD | Released Forecast Spread | -351 -492 28.73% | -427 -327 -30.59% | -404 -336 -20.3% | |
|
Net income Million TWD | Released Forecast Spread | -351 -492 28.73% | -332 | -427 -327 -30.6% | -404 -336 -20.3% |
|
EPS TWD | Released Forecast Spread | -2,91 -4,74 38.61% | -2,82 | -3,63 -2,79 -30.11% | -3,45 -2,85 -21.05% |
| Announcement Date | 28/03/22 | 13/05/22 | 30/08/22 | 14/11/22 |
| 14/05/2024 | CELCUITY INC.: Q1 2024 Earnings Release |
| 15/05/2024 | BIOCON LIMITED: Q4 2024 Earnings Release |
| 16/05/2024 14:00 | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 17/05/2024 12:00 | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 23/07/2024 | VIKING THERAPEUTICS, INC.: Q2 2024 Earnings Release (Projected) |
| 24/07/2024 | BIOCON LIMITED: Q1 2025 Earnings Release (Projected) |
| 25/07/2024 06:00 | ARGENX SE: Q2 2024 Earnings Release |
| 29/07/2024 | RHYTHM PHARMACEUTICALS, INC.: Q2 2024 Earnings Release (Projected) |
| 29/07/2024 | NEUROCRINE BIOSCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
| 29/07/2024 | CEREVEL THERAPEUTICS HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Tanvex BioPharma, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- 6541 Stock
- Calendar Tanvex BioPharma, Inc.
